Document ID: chunk:federal_register_of_legislation:F2025L00062:schedule:1:p49
Version: federal_register_of_legislation:F2025L00062
Segment Type: schedule
Provision Reference: sch 1 (pt 49/51)
Character Range: 155220–160503

twice daily (i.e., in combination with selpercatinib 40 mg). Selpercatinib 80 mg with a quantity of 112 units must be prescribed only where the dose is 160 mg twice daily to provide 28 days of treatment per dispensing. Prescribers should refer to the TGA PI for dosing and dose adjustments regimens.
C16285  P16285  CN16285  Saxagliptin with dapagliflozin  Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures
                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                         The treatment must be in combination with at least metformin; AND
                                                         The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor; AND
                                                         Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor.
C16288  P16288  CN16288  Hydroxocobalamin                Pernicious anaemia
                                                         Patient must identify as Aboriginal or Torres Strait Islander;
                                                         Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner.
C16289  P16289  CN16289  Hydroxocobalamin                Proven vitamin B12 deficiencies other than pernicious anaemia
                                                         Patient must identify as Aboriginal or Torres Strait Islander;
                                                         Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner.
C16290  P16290  CN16290  Saxagliptin with dapagliflozin  Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures
                                                         The treatment must be in combination with at least metformin; AND
                                                         The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor; AND
                                                         Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor.

[197] Schedule 5, entry for Abiraterone [GRP-29273]
insert as the first entry in the column headed "Brand": Abiraterone Sandoz
[198] Schedule 5, entry for Abiraterone [GRP-29283]
insert as the first entry in the column headed "Brand": Abiraterone Sandoz
[199] Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe
omit from the column headed "Brand": Adalicip
[200] Schedule 5, omit entries for Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides
[201] Schedule 5, entry for Amlodipine [GRP-19809]
substitute:
Amlodipine  GRP-19809  Tablet 10 mg (as besilate)  Oral  Amlo 10
                                                         Amlodipine APOTEX
                                                         Amlodipine GH
                                                         Amlodipine Sandoz
                                                         AMLODIPINE-WGR
                                                         APO-Amlodipine
                                                         APX-AMLODIPINE
                                                         Blooms Amlodipine
                                                         Blooms the Chemist Amlodipine
                                                         Nordip
                                                         Norvasc
                                                         NOUMED AMLODIPINE
                                                         Pharmacor Amlodipine

[202] Schedule 5, after entry for Calcipotriol with betamethasone
insert:
Calcipotriol with betamethasone  GRP-29366  Foam containing calcipotriol